MarketCap
Facebook
X
Telegram
Harrow Health Revenue | HROW
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Harrow Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 272 M | 200 M | 130 M | 88.6 M | 72.5 M | 48.9 M | 51.2 M | 41.4 M | 26.8 M | 19.9 M | 9.72 M | 1.66 M | 10 K | 100 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 272 M | 10 K | 68.8 M |
Quarterly Revenue Harrow Health
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 63.7 M | 44.2 M | - | 71.6 M | 63.7 M | 47.8 M | - | 49.3 M | 48.9 M | 34.6 M | - | 34.3 M | 33.5 M | 26.1 M | - | 22.8 M | 23.3 M | 22.1 M | - | 18.7 M | 18.1 M | 15.4 M | - | 14.4 M | 8.06 M | 11.8 M | - | 12.8 M | 13.5 M | 12.3 M | - | 10.7 M | 10.4 M | 8.86 M | - | 6.48 M | 6.86 M | 6.1 M | - | 4.86 M | 4.91 M | 4.38 M | - | 2.68 M | 1.97 M | 1.56 M | - | 441 K | 667 K | 2 K | - | 2.5 K | 2.5 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 71.6 M | 2 K | 19.6 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M |  USA |
 |
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M | USA |
 |
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
2.03 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | USA |
 |
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | USA |
 |
OptiNose
OPTN
|
78.2 M | - | - | $ 1.08 B | USA |
 |
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | USA |
 |
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M |  Irlanda |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | - | 0.86 % | $ 117 M | USA |
 |
Bausch Health Companies
BHC
|
10.3 B | $ 5.94 | 1.28 % | $ 2.2 B |  Canada |
 |
China Pharma Holdings
CPHI
|
4.14 M | $ 0.78 | 1.38 % | $ 3.35 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
13.7 M | $ 6.53 | 2.19 % | $ 97 M | USA |
 |
Cronos Group
CRON
|
147 M | $ 3.22 | 2.55 % | $ 1.23 B | Canada |
 |
Emergent BioSolutions
EBS
|
743 M | $ 6.39 | 2.4 % | $ 342 M | USA |
 |
Evolus
EOLS
|
297 M | $ 8.05 | 2.68 % | $ 519 M | USA |
 |
Organogenesis Holdings
ORGO
|
564 M | $ 1.48 | 1.01 % | $ 188 M | USA |
 |
Pacira BioSciences
PCRX
|
726 M | $ 25.2 | 0.02 % | $ 1.12 B | USA |
 |
Perrigo Company plc
PRGO
|
4.25 B | $ 13.98 | 2.23 % | $ 1.94 B | USA |
 |
Rockwell Medical
RMTI
|
69.3 M | $ 7.94 | 0.75 % | $ 286 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.13 K | $ 4.5 | 0.11 % | $ 178 M | USA |
 |
SCYNEXIS
SCYX
|
20.6 M | $ 4.6 | 2.69 % | $ 230 M | USA |
 |
Solid Biosciences
SLDB
|
8.09 M | $ 9.03 | 3.79 % | $ 790 M | USA |
 |
Sundial Growers
SNDL
|
946 M | $ 1.37 | 1.87 % | $ 354 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
19.5 M | $ 1.29 | 2.29 % | $ 2.17 M | USA |
 |
Tilray
TLRY
|
821 M | $ 4.14 | 3.11 % | $ 3.69 B | Canada |
 |
TherapeuticsMD
TXMD
|
3.02 M | $ 2.16 | 0.23 % | $ 25 M | USA |
 |
Veru
VERU
|
16.9 M | $ 2.37 | 0.4 % | $ 34.7 M | USA |
 |
Viatris
VTRS
|
14.3 B | $ 16.69 | 1.09 % | $ 19.2 B | USA |
 |
cbdMD
YCBD
|
19.2 M | $ 0.48 | 0.94 % | $ 1.93 M | USA |
 |
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | USA |
 |
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
874 K | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Canopy Growth Corporation
CGC
|
285 M | $ 0.94 | 1.32 % | $ 280 M | Canada |
 |
OrganiGram Holdings
OGI
|
160 M | $ 1.08 | 2.38 % | $ 103 M | Canada |
 |
Aurora Cannabis
ACB
|
175 M | $ 3.83 | 2.27 % | $ 210 M | Canada |
 |
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
28 K | - | 7.5 % | $ 6.35 M | USA |
 |
Assertio Holdings
ASRT
|
119 M | - | - | $ 150 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
10.2 M | - | - | $ 36.6 M | USA |
 |
Jupiter Wellness
JUPW
|
2.12 M | - | - | $ 33.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
925 K | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
4.34 M | - | - | $ 5.07 M | USA |
 |
Zomedica Corp.
ZOM
|
32 M | - | -0.21 % | $ 98 M | USA |